Board approves subsidiary investments, independent director term ends

Management Changes View source PDF Explain this filing

FABTECH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹156.89

prior close

₹158.74

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+0.2% vs market

Medical Equipment & Supplies peers, median of 11sector-0.3%-0.2% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Microcap 250 and 0.2 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.4

15m

-0.1

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-0.6+0.2-0.3-0.2

Next day

+0.5-0.9+1.3-1.2+1.7

-0.3+0.1-0.4-0.3+0.0

+0.1+0.3-0.2-0.2+0.3

+2.8+1.2+1.6-0.6+3.4

+5.4+0.8+4.5+0.3+5.1

+3.6+0.3+3.3+1.0+2.5

15d

-2.1-0.2-1.8+5.2-7.3

-5.5+0.6-6.1+3.5-8.9

-5.2+4.7-9.8+4.6-9.8

-7.2+5.4-12.6+20.5-27.7

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fabtech Technologies board approved additional investments in two wholly-owned subsidiaries: up to Rs 24 crore in Fabtech Technologies LLC (UAE-based EPC unit with nil turnover and negative networth) and Rs 2.49 crore in FT Institutions Pvt Ltd (pharma subsidiary with Rs 12.6 crore turnover in FY26). Independent Director Mr. Shyam Khante's term ended on June 25, 2026. Board also reconstituted Audit, NRC and CSR committees effective June 26 and raised borrowing limits (within Section 180(1)(c) cap, no shareholder approval needed).

Likely market impact

Rs 24 crore into a loss-making UAE subsidiary with zero revenue is notable for investors; director exit and committee reconstitution are routine.